BeiGene | LinkedIn (original) (raw)

About us

BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter) and Facebook.

Industry

Biotechnology Research

Company size

10,001+ employees

Headquarters

Cambridge, MA

Type

Public Company

Founded

2010

Specialties

targeted therapy, immuno-oncology, hematology, oncology, and cancer

Locations

Primary
55 Cambridge Parkway
Suite 700W
Cambridge, MA 02142, US
Get directions
55 Challenger Rd
Ridgefield Park, New Jersey 07660, US
Get directions
1840 Gateway Drive
3nd Floor
San Mateo, CA 94404, US
Get directions
1900 Powell Street
Suite 500
Emeryville, CA 94608, US
Get directions
6A Jianguomenwai Avenue
22nd Floor, Tower D
Chaoyang District, Beijing, China 100022, CN
Get directions
30 Science Park Road
Zhong-Guan-Cun Life Science Park
Changping District, Beijing, Beijing 102206, CN
Get directions
218 Sangtian St.
4F, Building 6
Suzhou, Jiangsu 215025, CN
Get directions
1539 Nanjing West Road
Jing An Kerry Centre, Unit 1804, 18/F, Tower 2
Shanghai, Shanghai 200040, CN
Get directions
83 South Kangyao Road
Sino-Singapore Guangzhou Knowledge City
Huangpu District, Guangzhou, Guangdong 510130, CN
Get directions
Teichgässlein 9
5th Floor
Basel, Basel-Town 4058, CH
Get directions
66 Goulburn Street
Suite 11.01, Level 11
Sydney, 2000, AU
Get directions
Arquiteto Olavo Redig de Campos 105
29 Andar, Conj. 292
São Paulo, BR
Get directions
161 Bay St
Suite 2400
Toronto, ON M5J 2S1, CA
Get directions
Gangnam Bldg. 396 Seocho-daero, Seocho-gu
Unit 1404
Seoul, 0661, KR
Get directions
38 Beach Road #29-11, South Beach Tower
Singapore , 189767, SG
Get directions
Songren Road
4F, No.97
Taipei City, 11073, TW
Get directions
Nanjing E Rd
4F-1, No.386, Section 6
Taipei City, 11470, TW
Get directions
8170 Maple Lawn Blvd
Suite 160
Fulton, MD 20759, US
Get directions
311 Pennington Rocky Hill Rd
Hopewell , NJ 08534, US
Get directions
Arismendi 2441/43 – Ciudad Autónoma de
Buenos Aires, AR
Get directions
Miraflores 222, Piso 28 Norte
Santiago de Chile, CL
Get directions
Carretera Estatal 500, Km 30 (ATTA Microparque Industrial PyME) Bodega 7, Tierra Blanca, El Marqués
Santiago de Querétaro, MX
Get directions

Employees at BeiGene

Updates

As we celebrate the 5th anniversary of our BTK inhibitor’s approval, we’re proud to share that over 140,000 patients worldwide have been treated with this medicine across five different indications. Our commitment to expanding access and advancing cancer care remains at the heart of our mission. Today, our BTK inhibitor stands as the cornerstone of our hematology leadership, improving outcomes for patients with certain blood cancers in over 70 markets. Watch the video to learn more. #BloodCancer #BTKi #PatientsFirst
BeiGene reposted this

Founder, Chairman & CEO at BeiGene
4d
Today BeiGene unveiled our proposed company name change to BeOne Medicines Ltd., reaffirming our mission to unite the global community against cancer. The new name is part of a broader strategic growth plan that has enabled the Company’s fast rise to global leadership since its inception in 2010. Read my latest LinkedIn article for more background.
BeiGene Unveils Proposed Name Change to BeOne Medicines John V. Oyler on LinkedIn
176,034 followers
4d Edited
Today we unveiled our proposed name change to BeOne Medicines Ltd. Reaffirming our mission to unite the global community against cancer. Read the press release for full details: https://bit.ly/48Oxfyg
'I'm extremely proud to be part of this company because I know what we are doing is having a huge impact worldwide.' Our colleague, Gabrielle McEntee, shares her inspiration and motivation for working at BeiGene. Watch the video to discover more.
176,034 followers
6d Edited
BeiGene announces third quarter 2024 financial results and corporate updates. Read the press release for full details. https://bit.ly/48Ty7BY
As this season of Light The Night walks draw to a close, we’re inspired by the impact we’ve made together in support of The Leukemia & Lymphoma Society’s mission to end blood cancer. BeiGene was honored to serve as the National Presenting Sponsor of Survivorship and Hope, with colleagues walking alongside patients, families and communities nationwide to bring light to the darkness of cancer. Through nearly 100 events and the dedication of nearly 100,000 participants, this movement raised critical awareness and funds. With over $1.5 million contributed through our team efforts and sponsorship, we’re helping fuel LLS’s work to advance research, support patients and improve access to care. Watch the video to learn more about our journey together. #LightTheNight #TeamBeiGene #PatientsFirst
We’re in Houston this week with a poster at SITC 2024 highlighting preclinical data for our IL-15 prodrug. We designed this investigational molecule to remain inactive in circulation and become active at the tumor site, with the hope of killing cancer cells and reducing potential side effects. Read the scientific abstract here: https://bit.ly/4hyS9Wc #SITC2024

Join now to see what you are missing

Join now

Browse jobs

Stock

BGNE

November 18, 2024

NASDAQ

20 minutes delay

Open

186.92

Low

184.49

High

188.28

Data from Refinitiv

See more info on Bing